The QuidelOrtho NULEXA™ System has set a new standard for point-of-care respiratory molecular testing by being the first to deliver RT-PCR influenza + SARS results in less than 10 minutes.* That means providers can help deliver answers while patients are still in the clinic—without sacrificing the confidence of RT-PCR testing.

• Help support treatment decisions during the patient visit with RT-PCR influenza A, influenza B and SARS-CoV-2 results in less than 10 minutes^*
• Approximately one minute of hands-on time and a streamlined workflow help busy staff stay focused on patient care
• Direct sample-to-cartridge workflow minimizes handling steps and simplifies testing
• One cartridge. Three pathogens. Simultaneously assess influenza A, influenza B and SARS-CoV-2 from a single sample
• CLIA waived for point-of-care use.

^* As of June 16, 2026, based on date of FDA clearance and time to result for RT-PCR Influenza A/B + SARS-CoV-2 diagnostic tests for point-of-care settings. See quidelortho.com/global/en/products/nulexa-system/claims-matrix-June26.